Fused Imidazo[1,2‐d][1,2,4]Thiadiazolo[1,2,3]Triazoles: One‐Pot Synthesis, Anti‐Bacterial, Anti‐Biofilm and TLR4 Inhibitory Activities

ChemistrySelect, Journal Year: 2024, Volume and Issue: 9(32)

Published: Aug. 23, 2024

Abstract We developed and evaluated several new fused imidazo[1,2‐d][1,2,4]thiadiazolo[1,2,3]triazoles to see how they perform against bacteria biofilms. Some compounds showed acceptable activity compared the primary standard, Dicloxacillin. of demonstrated significant antibacterial S. aureus , with MIC values ranging from 1.56–12.5 μg/mL. also found anti‐biofilm properties in potent compounds. The results that derivatives 3‐(4‐fluorophenyl)imidazo[1,2‐d] [1,2,3] triazolo[1,5‐b][1,2,4]thiadiazole 8,8‐dioxide 3‐(3,5‐difluorophenyl)imidazo[1,2‐d][1,2,3]triazolo[1,5‐b][1,2,4] thiadiazole were strong agents effective MSSA MRSA biofilm growth inhibitors. conducted silico studies assess molecular interactions more TLR4 proteins (PDB: 3FXI, 3VQ1, 3RG1). Our findings revealed 3‐(4‐chloro‐3,5‐dimethoxyphenyl)imidazo[1,2‐d][1,2,3]triazolo[1,5‐b] [1,2,4]thiadiazole 8,8‐dioxide, 3‐(3,5‐dichlorophenyl)imidazo[1,2‐d] [1,2,3]triazolo[1,5‐b][1,2,4] 3‐(4‐(trifluoromethyl)phenyl)imidazo[1,2‐d][1,2,3]triazolo[1,5‐b][1,2,4] exhibited binding than dicloxacillin. ADME examined this study could potentially inhibit cytochrome P450 CYP2C19 isoform.

Language: Английский

Synthesis and Evaluation of 3,5‐Disubstituted‐1,2,4‐Oxadiazolyl Benzamides as Potential Anti‐Breast Cancer Agents: In Vitro and In Silico Studies

Chemistry & Biodiversity, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 4, 2024

Herein, the synthesis, anti-cancer evaluation, and in silico studies of a series 1,2,4-oxadiazole compounds (8-15) are disclosed. The synthesized molecules were tested vitro for activity against MCF-7, MDA-MB-231, HeLa, Ishikawa cell lines human embryonic kidney (HEK-293) lines. Among compounds, 9 15 exhibited significant cytotoxicity, with IC

Language: Английский

COF‐SO3H‐Catalyzed Synthesis of Pyrazoline‐Pyridine Hybrids with Dual Antioxidant and Anti‐Inflammatory Activity Targeting PDE4B

Chemistry & Biodiversity, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 11, 2024

Abstract This study explores new anti‐inflammatory agents by synthesizing pyrazoline‐pyridine hybrids with N‐butylsulfonated covalent organic framework (COF‐SO 3 H) as a recyclable catalyst, achieving excellent yields in just one minute. The protocol was successfully scaled up to multi‐gram scale, highlighting its robustness and efficiency, it operates without the need for column chromatography. Among synthesized hybrids, compound 5d , hybrid bearing an indole moiety, emerged potent antioxidant agent. It effectively inhibited PDE4B activation IC 50 value of 99.38 nM, adversely affecting HEK cells. Compound demonstrated dual activity significantly reducing ROS production restoring mitochondrial health LPS‐stimulated A549 cells, while also downregulating IL‐1β NF‐ĸB/p65 expression In silico studies confirmed ’s strong binding PDE4B, stable RMSD RMSF values, indicating potential effective inhibitor. exhibited favorable physicochemical properties, met drug‐likeness criteria, showed low toxicity predicted silico. These findings suggest that has significant therapeutic agent inflammatory diseases due activities.

Language: Английский